AstraZeneca (AZN) officer Sharma Mani sells 11,893 Ordinary Shares in open market

Rhea-AI Filing Summary

ASTRAZENECA PLC officer Sharma Mani reported an open-market sale of 11,893 Ordinary Shares on May 20, 2026 at an average price of $185.78 per share, based on a GBP139.35 price and a stated currency conversion rate. After this transaction, Mani directly holds 19,262.4659 Ordinary Shares.

Insider Trade Summary

Net Seller: 11,893 shares ($2,209,482)

Net Sell 1 txn

Insider Sharma Mani

Role See Remarks

Sold 11,893 shs ($2.21M)

Type	Security	Shares	Price	Value
Sale	Ordinary Shares	11,893	$185.78	$2.21M

Holdings After Transaction: Ordinary Shares — 19,262.466 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Shares sold: 11,893 shares Sale price per share: $185.78 per share Post-transaction holdings: 19,262.4659 shares +2 more

5 metrics

Shares sold 11,893 shares Open-market sale on May 20, 2026

Sale price per share $185.78 per share Average price for Ordinary Shares sold

Post-transaction holdings 19,262.4659 shares Direct ownership after sale

GBP sale price GBP139.35 per share Underlying sterling price referenced in footnote

FX conversion rate GBP1.0000 = $1.3332 Rate on May 15, 2026 from Federal Reserve Board

Key Terms

open-market sale, Ordinary Shares, Form 4, conversion rate

4 terms

open-market sale financial

"describes it as an open-market sale of 11,893 AstraZeneca Ordinary Shares"

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

Ordinary Shares financial

"reported an open-market sale of 11,893 Ordinary Shares on May 20, 2026"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

Form 4 regulatory

"according to a Form 4 filing"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

conversion rate financial

"converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3332"

Conversion rate is the proportion of items, people or contracts that take a desired action out of the total possible — for example the share of website visitors who make a purchase, or the number of convertible bonds that are exchanged for shares. Investors care because it measures how effectively a business or financial instrument turns opportunity into real outcomes, like sales or share issuance, which directly affects revenue, cash flow and ownership dilution.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Sharma Mani

(Last) (First) (Middle)

C/O ASTRAZENECA PLC 1 FRANCIS

CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS

(Street)

CAMBRIDGE CB2 0AA

(City) (State) (Zip)

UNITED KINGDOM

(Country)

2. Issuer Name and Ticker or Trading Symbol
ASTRAZENECA PLC [ AZN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/20/2026		S		11,893	D	$185.78(1)	19,262.4659	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the sale of shares at a price of GBP139.35, which has been converted from British pounds sterling to United States dollars at a conversion rate of GBP1.0000 to $1.3332 on May 15, 2026 as published by the Board of Governors of the Federal Reserve System.

Remarks:

SVP, Group Controller and Head of Global Finance Services

	/s/ Mani Sharma	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did AstraZeneca (AZN) report for Sharma Mani?

AstraZeneca officer Sharma Mani reported an open-market sale of 11,893 Ordinary Shares. The trade occurred on May 20, 2026 at an average price of $185.78 per share, and Mani continues to hold 19,262.4659 Ordinary Shares directly after the sale.

At what price were the AstraZeneca (AZN) shares sold by Sharma Mani?

The 11,893 AstraZeneca Ordinary Shares were sold at an average price of $185.78. This reflects a price of GBP139.35 converted to U.S. dollars using a GBP1.0000 to $1.3332 exchange rate published by the Federal Reserve Board on May 15, 2026.

How many AstraZeneca (AZN) shares does Sharma Mani hold after the reported sale?

Following the May 20, 2026 transaction, Sharma Mani directly holds 19,262.4659 AstraZeneca Ordinary Shares. This figure represents the remaining direct ownership position disclosed in the Form 4 after selling 11,893 shares in an open-market transaction at $185.78 per share.

Was the AstraZeneca (AZN) transaction by Sharma Mani a buy or a sell?

The transaction was a sale. The Form 4 shows a transaction code “S” and describes it as an open-market sale of 11,893 AstraZeneca Ordinary Shares at an average price of $185.78 per share, reducing Sharma Mani’s direct holdings to 19,262.4659 shares.

Did Sharma Mani’s AstraZeneca (AZN) Form 4 involve derivatives or only Ordinary Shares?

The Form 4 reports a transaction only in AstraZeneca Ordinary Shares. It shows no derivative securities, and the derivative summary is empty, indicating there were no option exercises, conversions, or other derivative-related transactions disclosed in this particular filing.